It is generally perceived that the determination of blood-based NfL does not stand out for its contribution to the diagnosis of the disease (mean ± SD: 1.8 ± 0.8) as it is not able to differentiate MS from other neurological diseases. This evidence concerns the gene NEFL and myeloid sarcoma.